293 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Not yet recruiting International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Condition: Acute Myeloid Leukaemia
Interventions: Drug: Gemtuzumab ozogamicin;   Drug: Liposomal daunorubicin;   Drug: Mitoxantrone;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Busulfan;   Drug: Cyclophosphamide
2 Recruiting Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
Condition: Pineoblastoma
Interventions: Drug: Temozolomide;   Drug: Irinotecan;   Drug: Dasatinib;   Drug: Rapamycin
3 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
4 Active, not recruiting Study of Intravenous RXDX-107 in Patients With Solid Tumors
Condition: Solid Tumor
Intervention: Drug: RXDX-107
5 Recruiting Chidamide Plus R-CHOP in Elderly DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Chidamide
6 Recruiting Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: bendamustine, rituximab
7 Recruiting Reduced Chemotherapy in Low Risk DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone
8 Not yet recruiting Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Radiation: Fractionated total body irradiation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Drug: Melphalan;   Drug: Granulocyte-colony stimulating factor;   Procedure: Stem cell transplant;   Drug: Azacitidine
9 Not yet recruiting Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Conditions: Diffuse Large B Cell Lymphoma;   Primary Mediastinal (Thymic) Large B-cell Lymphoma;   Transformed Indolent Lymphoma;   Recurrent Disease;   Refractory Cancer
Intervention: Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
10 Active, not recruiting Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Conditions: Myelodysplastic Syndrome;   Allogeneic Hematopoietic Stem Cell Transplantation;   Conditioning
Interventions: Drug: Decitabine;   Drug: Busulfan (BU);   Drug: Cyclophosphamide (CY)
11 Recruiting Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia
Condition: Glaucoma
Intervention: Drug: Mitomycin-C (MMC)
12 Not yet recruiting A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Letrozole;   Drug: Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
13 Not yet recruiting A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
14 Not yet recruiting A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Durvalumab;   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Bendamustine
15 Not yet recruiting Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)
Condition: Sarcoma
Interventions: Drug: Rolapitant;   Drug: Fosaprepitant;   Behavioral: Questionnaires;   Drug: Dexamethasone;   Drug: Ondansetron;   Drug: Doxorubicin;   Drug: Mesna;   Drug: Ifosfamide;   Drug: Vincristine
16 Recruiting Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Cytarabine;   Drug: Pegfilgrastim;   Procedure: Leukapheresis;   Drug: Filgrastim;   Procedure: Autologous stem cell transplant
17 Not yet recruiting Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)
Conditions: Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
18 Recruiting Protocol for the Treatment of Metastatic Ewing Sarcoma
Condition: Ewing's Sarcoma (ES)
Interventions: Drug: TEMIRI;   Drug: ADM;   Drug: IFO;   Drug: CYC;   Drug: ETO;   Drug: BUMEL;   Drug: VIN
19 Not yet recruiting A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
20 Not yet recruiting Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Conditions: Fibrolamellar Hepatocellular Carcinoma;   Hepatocellular Carcinoma (Fibrolamellar Variant);   Hepatocellular Carcinoma
Interventions: Procedure: living related donor partial liver transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow transplant from same donor;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: mycophenolate mofetil;   Drug: Prednisone;   Drug: Antithymocyte globulin;   Drug: fludarabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years